| フルテキストURL | fulltext.pdf |
|---|---|
| 著者 | Sakaeda, Kazuma| Sadahira, Takuya| Maruyama, Yuki| Iwata, Takehiro| Watanabe, Masami| Wada, Koichiro| Araki, Motoo| |
| キーワード | antimicrobial resistance Escherichia coli urinary tract infections flomoxef ST131 |
| 発行日 | 2023-03-06 |
| 出版物タイトル | Antibiotics |
| 巻 | 12巻 |
| 号 | 3号 |
| 出版者 | MDPI |
| 開始ページ | 522 |
| ISSN | 2079-6382 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © 2023 by the authors. |
| 論文のバージョン | publisher |
| PubMed ID | 36978389 |
| DOI | 10.3390/antibiotics12030522 |
| Web of Science KeyUT | 000952995400001 |
| 関連URL | isVersionOf https://doi.org/10.3390/antibiotics12030522 |
| フルテキストURL | fulltext.pdf |
|---|---|
| 著者 | Sun, Jingkai| Lin, Wenfeng| Li, Chaoming| Ueki, Hideo| Xue, Ruizhi| Sadahira, Takuya| Hu, Hao| Wada, Koichiro| Li, Na| Liu, Chunxiao| Araki, Motoo| Xu, Abai| Huang, Peng| |
| キーワード | Posaconazole cell cycle autophagy rhabdomyosarcoma hedgehog proteins |
| 発行日 | 2021-09-30 |
| 出版物タイトル | American Journal of Cancer Research |
| 巻 | 11巻 |
| 号 | 9号 |
| 出版者 | e-Century Publishing Corporation |
| 開始ページ | 4528 |
| 終了ページ | 4540 |
| ISSN | 2156-6976 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | AJCR (c)2021 e-Century Publishing Corp. |
| 論文のバージョン | publisher |
| PubMed ID | 34659903 |
| Web of Science KeyUT | 000707716300029 |
| JaLCDOI | 10.18926/AMO/62820 |
|---|---|
| フルテキストURL | 75_6_763.pdf |
| 著者 | Iwata, Takehiro| Sadahira, Takuya| Maruyama, Yuki| Sekito, Takanori| Yoshinaga, Kasumi| Watari, Shogo| Nagao, Kentaro| Kawada, Tatsushi| Tominaga, Yusuke| Nishimura, Shingo| Takamoto, Atsushi| Sako, Tomoko| Edamura, Kohei| Kobayashi, Yasuyuki| Araki, Motoo| Ishii, Ayano| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo| Wada, Koichiro| |
| 抄録 | The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants. |
| キーワード | genitourinary tract infections fluoroquinolone resistance extended-spectrum beta-lactamase |
| Amo Type | Clinical Study Protocol |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2021-12 |
| 巻 | 75巻 |
| 号 | 6号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 763 |
| 終了ページ | 766 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2021 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 34955548 |
| Web of Science KeyUT | 000735319800006 |
| NAID | 120007180272 |
| JaLCDOI | 10.18926/AMO/62810 |
|---|---|
| フルテキストURL | 75_6_705.pdf |
| 著者 | Iwata, Takehiro| Maruyama, Yuki| Kawada, Tatsushi| Sadahira, Takuya| Katayama, Satoshi| Takamoto, Atsushi| Sako, Tomoko| Wada, Koichiro| Edamura, Kohei| Kobayashi, Yasuyuki| Araki, Motoo| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo| |
| 抄録 | Optimal neoadjuvant hormone therapy (NHT) for reducing prostate cancer (PC) patients’ prostate volume pre-brachytherapy is controversial. We evaluated the differential impact of neoadjuvant gonadotropin-releasing hormone (GnRH) antagonist versus agonist on post-brachytherapy testosterone recovery in 112 patients treated pre-brachytherapy with NHT (GnRH antagonist, n=32; GnRH agonists, n=80) (Jan. 2007-June 2019). We assessed the effects of patient characteristics and a GnRH analogue on testosterone recovery with logistic regression and a propensity score analysis (PSA). There was no significant difference in the rate of testosterone recovery to normal levels (> 300 ng/dL) between the GnRH antagonist and agonists (p=0.07). The GnRH agonists induced a significantly more rapid testosterone recovery rate at 3 months post-brachytherapy versus the GnRH antagonist (p<0.0001); there was no difference in testosterone recovery at 12 months between the GnRH antagonist/agonists (p=0.8). In the multivariate analysis, no actor was associated with testosterone recovery. In the PSA, older age and higher body mass index (BMI) were significantly associated with longer testosterone recovery. Post-brachytherapy testosterone recovery was quicker with the neoadjuvant GnRH agonists than the antagonist, and the testosterone recovery rate was significantly associated with older age and higher BMI. Long-term follow-ups are needed to determine any differential effects of GnRH analogues on the quality of life of brachytherapy-treated PC patients. |
| キーワード | testosterone recovery GnRH antagonist GnRH agonist brachytherapy prostate cancer |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2021-12 |
| 巻 | 75巻 |
| 号 | 6号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 705 |
| 終了ページ | 711 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | Copyright Ⓒ 2021 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 34955538 |
| Web of Science KeyUT | 000735297900006 |
| NAID | 120007180282 |
| フルテキストURL | fulltext.pdf |
|---|---|
| 著者 | Lin, Wenfeng| Sun, Jingkai| Sadahira, Takuya| Xu, Naijin| Wada, Koichiro| Liu, Chunxiao| Araki, Motoo| Xu, Abai| Watanabe, Masami| Nasu, Yasutomo| Huang, Peng| |
| キーワード | Urothelial bladder cancer doxorubicin cisplatin chemoresistance nitroxoline STAT3 |
| 発行日 | 2021-07-25 |
| 出版物タイトル | International Journal of Biological Sciences |
| 巻 | 17巻 |
| 号 | 12号 |
| 出版者 | Ivyspring International Publisher |
| 開始ページ | 3255 |
| 終了ページ | 3267 |
| ISSN | 1449-2288 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © The author(s). |
| 論文のバージョン | publisher |
| DOI | 10.7150/ijbs.63125 |
| Web of Science KeyUT | 000682847000007 |
| 関連URL | isVersionOf https://doi.org/10.7150/ijbs.63125 |
| フルテキストURL | fulltext20210721-2.pdf figure20210721-2.pdf |
|---|---|
| 著者 | Watari, Shogo| Araki, Motoo| Wada, Koichiro| Yoshinaga, Kasumi| Maruyama, Yuki| Mitsui, Yosuke| Sadahira, Takuya| Kubota, Risa| Nishimura, Shingo| Kobayashi, Yasuyuki| Takeuchi, Hidemi| Tanabe, Katsuyuki| Kitagawa, Masashi| Morinaga, Hiroshi| Kitamura, Shinji| Sugiyama, Hitoshi| Wada, Jun| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo| |
| 備考 | © 2021 Published by Elsevier Inc. This manuscript version is made available under the CC-BY-NC-ND 4.0 License. http://creativecommons.org/licenses/by-nc-nd/4.0/. This is the accepted manuscript version. The formal published version is available at [https://doi.org/10.1016/j.transproceed.2021.03.043] . | |
| 発行日 | 2021-4-28 |
| 出版物タイトル | Transplantation Proceedings |
| 巻 | 53巻 |
| 号 | 5号 |
| 出版者 | Elsevier BV |
| 開始ページ | 1494 |
| 終了ページ | 1500 |
| ISSN | 0041-1345 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 論文のバージョン | author |
| PubMed ID | 33931247 |
| DOI | 10.1016/j.transproceed.2021.03.043 |
| Web of Science KeyUT | 000668604400017 |
| 関連URL | isVersionOf https://doi.org/10.1016/j.transproceed.2021.03.043 |
| フルテキストURL | fulltext20210625-1.pdf |
|---|---|
| 著者 | Matsuo, Toshihiko| Tanaka, Takehiro| Nakamura, Aya| Wada, Koichiro| |
| キーワード | prostate cancer choroidal/uveal tumor choroidal/uveal metastasis radiation surgical castration complete remission hormonal therapy literature review prostate-specific antigen PSA positron emission tomography PET |
| 発行日 | 2021-06-23 |
| 出版物タイトル | Journal of Investigative Medicine High Impact Case Reports |
| 巻 | 8巻 |
| 出版者 | American Federation for Medical Research |
| 開始ページ | 1 |
| 終了ページ | 8 |
| ISSN | 2324-7096 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © 2021 American Federation for Medical Research |
| 論文のバージョン | publisher |
| PubMed ID | 34159819 |
| NAID | 120007089816 |
| DOI | 10.1177/23247096211026471 |
| 関連URL | isVersionOf https://doi.org/10.1177/23247096211026471 |
| フルテキストURL | fulltext.pdf |
|---|---|
| 著者 | Yoshinaga, Kasumi| Araki, Motoo| Wada, Koichiro| Sekito, Takanori| Watari, Shogo| Maruyama, Yuki| Mitsui, Yosuke| Sadahira, Takuya| Kubota, Risa| Nishimura, Shingo| Edamura, Kohei| Kobayashi, Yasuyuki| Tanabe, Katsuyuki| Takeuchi, Hidemi| Kitagawa, Masashi| Kitamura, Shinji| Wada, Jun| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo| |
| キーワード | diabetes mellitus kidney function kidney transplantation marginal donor |
| 発行日 | 2021-06-08 |
| 出版物タイトル | Immunity Inflammation and Disease |
| 出版者 | Wiley |
| ISSN | 2050-4527 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © 2021 The Authors. |
| 論文のバージョン | publisher |
| PubMed ID | 34102025 |
| NAID | 120007053366 |
| DOI | 10.1002/iid3.470 |
| Web of Science KeyUT | 000658836600001 |
| 関連URL | isVersionOf https://doi.org/10.1002/iid3.470 |
| フルテキストURL | fulltext20210603-2.pdf |
|---|---|
| 著者 | Matsumoto, Jun| Kotera, Yumi| Watari, Shogo| Takeuchi, Koichi| Ueki, Hideo| Koyama, Toshihiro| Wada, Koichiro| Fujiyoshi, Masachika| Nasu, Yasutomo| Ariyoshi, Noritaka| |
| キーワード | human cytochrome P450 CYP3A renal cell carcinoma treatment outcome |
| 発行日 | 2021-5 |
| 出版物タイトル | Anticancer Research |
| 巻 | 41巻 |
| 号 | 5号 |
| 出版者 | International Institute of Anticancer Research |
| 開始ページ | 2511 |
| 終了ページ | 2521 |
| ISSN | 0250-7005 |
| NCID | AA10625860 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | Copyright © 2021 by The International Institute of Anticancer Research |
| 論文のバージョン | publisher |
| PubMed ID | 33952479 |
| DOI | 10.21873/anticanres.15029 |
| Web of Science KeyUT | 000648665800021 |
| 関連URL | isVersionOf https://doi.org/10.21873/anticanres.15029 |
| フルテキストURL | fulltext.pdf |
|---|---|
| 著者 | Wada, Koichiro| Araki, Motoo| Tanimoto, Ryuta| Sadahira, Takuya| Watari, Shogo| Maruyama, Yuki| Mitsui, Yosuke| Nakajima, Hirochika| Acosta, Herik| Katayama, Satoshi| Iwata, Takehiro| Nishimura, Shingo| Takamoto, Atsushi| Sako, Tomoko| Edamura, Kohei| Kobayashi, Yasuyuki| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo| |
| キーワード | Photodynamic diagnosis 5-Aminolevulinic acid ALA-PDD Upper urinary tract urothelial carcinoma VISERA ELITE video system |
| 発行日 | 2021-03-25 |
| 出版物タイトル | BMC urology |
| 巻 | 21巻 |
| 号 | 1号 |
| 出版者 | BMC |
| 開始ページ | 45 |
| ISSN | 1471-2490 |
| NCID | AA12035460 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 著作権者 | © The Author(s) 2021. |
| 論文のバージョン | publisher |
| PubMed ID | 33765999 |
| NAID | 120007008530 |
| DOI | 10.1186/s12894-021-00819-2 |
| Web of Science KeyUT | 000632906900001 |
| 関連URL | isVersionOf https://doi.org/10.1186/s12894-021-00819-2 |
| フルテキストURL | fulltext.pdf Fig_1.pptx Fig_2.pptx |
|---|---|
| 著者 | Maruyama, Yuki| Araki, Motoo| Wada, Koichiro| Yoshinaga, Kasumi| Mitsui, Yosuke| Sadahira, Takuya| Nishimura, Shingo| Edamura, Kohei| Kobayashi, Yasuyuki| Watanabe, Masami| Watanabe, Toyohiko| Monga, Manoj| Nasu, Yasutomo| Kumon, Hiromi| |
| キーワード | urothelial carcinoma urinary tract cancer ureteroscopy long-term survival renal pelvis ureter |
| 備考 | This is a pre-copyedited, author-produced version of an article accepted for publication in Japanese Journal of Clinical Oncology following peer review. The version of record Long-term ureteroscopic management of upper tract urothelial carcinoma: 28-year single-centre experience, Japanese Journal of Clinical Oncology, Volume 51, Issue 1, January 2021, Pages 130–137 is available online at: https://doi.org/10.1093/jjco/hyaa132.| |
| 発行日 | 2020-7-27 |
| 出版物タイトル | Japanese Journal of Clinical Oncology |
| 巻 | 51巻 |
| 号 | 1号 |
| 出版者 | Oxford University Press |
| 開始ページ | 130 |
| 終了ページ | 137 |
| ISSN | 0368-2811 |
| NCID | AA00690866 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| OAI-PMH Set | 岡山大学 |
| 論文のバージョン | author |
| PubMed ID | 32715306 |
| DOI | 10.1093/jjco/hyaa132 |
| Web of Science KeyUT | 000608420900018 |
| 関連URL | isVersionOf https://doi.org/10.1093/jjco/hyaa132 |
| JaLCDOI | 10.18926/AMO/54989 |
|---|---|
| フルテキストURL | 71_2_187.pdf |
| 著者 | Takamoto, Atsushi| Araki, Motoo| Wada, Koichiro| Sugimoto, Morito| Kobayashi, Yasuyuki| Sasaki, Katsumi| Watanabe, Toyohiko| Nasu, Yasutomo| |
| 抄録 | We report the case of a 58-year-old Japanese man with bilateral synchronous renal cell carcinoma (RCC). The diameters of the right and left tumors were 56 and 69 mm, respectively. Both tumors were endophytic. Cryoablation with prophylactic embolization was performed for the left tumor, and 1 month later, a right open partial nephrectomy was performed. No recurrence was observed during a 16-month follow-up, and the serum creatinine level has been stable. The prognosis of bilateral synchronous RCC is better than that of dialysis patients. The novel approach of combining cryoablation and partial nephrectomy can achieve good cancer control and renal function in bilateral RCC. |
| キーワード | cryoablation multiple renal masses nephron-sparing surgery renal cell carcinoma synchronous multiple primary |
| Amo Type | Case Report |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2017-04 |
| 巻 | 71巻 |
| 号 | 2号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 187 |
| 終了ページ | 190 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2017 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 28420902 |
| JaLCDOI | 10.18926/AMO/54982 |
|---|---|
| フルテキストURL | 71_2_135.pdf |
| 著者 | Mori, Akihiro| Watanabe, Masami| Sadahira, Takuya| Kobayashi, Yasuyuki| Ariyoshi, Yuichi| Ueki, Hideo| Wada, Koichiro| Ochiai, Kazuhiko| Li, Shun-Ai| Nasu, Yasutomo| |
| 抄録 | The cluster of differentiation 147 (CD147), also known as EMMPRIN, is a key molecule that promotes cancer progression. We previously developed an adenoviral vector encoding a tumor suppressor REIC/Dkk-3 gene (Ad-REIC) for cancer gene therapy. The therapeutic effects are based on suppressing the growth of cancer cells, but, the underlying molecular mechanism has not been fully clarified. To elucidate this mechanism, we investigated the effects of Ad-REIC on the expression of CD147 in LNCaP prostate cancer cells. Western blotting revealed that the expression of CD147 was significantly suppressed by Ad-REIC. Ad-REIC also suppressed the cell growth of LNCaP cells. Since other researchers have demonstrated that phosphorylated mitogen-activated protein kinases (MAPKs) and c-Myc protein positively regulate the expression of CD147, we investigated the correlation between the CD147 level and the activation of MAPK and c-Myc expression. Unexpectedly, no positive correlation was observed between CD147 and its possible regulators, suggesting that another signaling pathway was involved in the downregulation of CD147. This is the first study to show the downregulation of CD147 by Ad-REIC in prostate cancer cells. At least some of the therapeutic effects of Ad-REIC may be due to the downregulation of the cancer-progression factor, CD147. |
| キーワード | prostate cancer REIC/Dkk-3 CD147 cell growth p38 MAP kinase |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2017-04 |
| 巻 | 71巻 |
| 号 | 2号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 135 |
| 終了ページ | 142 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2017 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 28420895 |
| JaLCDOI | 10.18926/AMO/54508 |
|---|---|
| フルテキストURL | 70_4_299.pdf |
| 著者 | Wada, Koichiro| Uehara, Shinya| Ishii, Ayano| Sadahira, Takuya| Yamamoto, Masumi| Mitsuhata, Ritsuko| Takamoto , Atsushi| Araki, Motoo| Kobayashi, Yasuyuki| Watanabe, Masami| Watanabe, Toyohiko| Hotta, Katsuyuki| Nasu, Yasutomo| |
| 抄録 | Urinary tract infections (UTIs) are the most common bacterial infections in women, and many patients experience frequent recurrence. The aim of this report is to introduce an on-going prospective phase II clinical trial performed to evaluate the preventive effectiveness of Lactobacillus vaginal suppositories for prevention of recurrent cystitis. Patients enrolled in this study are administered vaginal suppositories containing the GAI 98322 strain of Lactobacillus crispatus every 2 days or 3 times a week for one year. The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse events. Recruitment began in December 2013 and target sample size is 20 participants. |
| キーワード | probiotics lactobacilli Lactobacillus crispatus urinary tract infection vaginal suppository |
| Amo Type | Clinical Study Protocols |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2016-08 |
| 巻 | 70巻 |
| 号 | 4号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 299 |
| 終了ページ | 302 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2016 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 27549677 |
| Web of Science KeyUT | 000384748600012 |
| JaLCDOI | 10.18926/AMO/54507 |
|---|---|
| フルテキストURL | 70_4_295.pdf |
| 著者 | Araki, Motoo| Wada, Koichiro| Mitsui, Yosuke| Kubota, Risa| Yoshioka, Takashi| Ariyoshi, Yuichi| Kobayashi, Yasuyuki| Kitagawa, Masashi| Tanabe, Katsuyuki| Sugiyama, Hiroshi| Wada, Jun| Watanabe, Masami| Watanabe, Toyohiko| Hotta, Katsuyuki| Nasu, Yasutomo| |
| 抄録 | Although graft survival following renal transplantation (RTx) has improved, outcomes following highrisk RTx are variable. Preexisting antibodies, including donor-specific antibodies (DSA), play an important role in graft dysfunction and survival. We have designed a study to investigate the safety and efficacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients. Major eligibility criteria include: 1) major and minor ABO blood group mismatch, 2) positive DSA. Thirty-five patients will receive 200 mg/body of rituximab. The primary endpoint is the incidence of B cell depletion. This study will clarify whether rituximab is efficacious in improving graft survival in high-risk RTx recipients. |
| キーワード | end-stage renal disease immunosuppression kidney transplantation |
| Amo Type | Clinical Study Protocols |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2016-08 |
| 巻 | 70巻 |
| 号 | 4号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 295 |
| 終了ページ | 297 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2016 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 27549676 |
| Web of Science KeyUT | 000384748600011 |
| JaLCDOI | 10.18926/AMO/54423 |
|---|---|
| フルテキストURL | 70_3_223.pdf |
| 著者 | Ebara, Shin| Kobayashi, Yasuyuki| Sasaki, Katsumi| Araki, Motoo| Sugimoto, Morito| Wada, Koichirou| Fujio, Kei| Takamoto, Atsushi| Watanabe, Toyohiko| Yanai, Hiroyuki| Nasu, Yasutomo| |
| 抄録 | The present case report describes a case of recurrent and advanced urachal carcinoma including neuroendocrine features with iliac bone metastasis after partial cystectomy and adjuvant chemotherapy consisting of irinotecan and cisplatin in a 32-year-old man. He received gemcitabine/cisplatin/ paclitaxel (GCP) combination chemotherapy, consisting of gemcitabin (1,000mg/m2) on day 1, 8, cisplatin (70mg/m2) on day 1, and paclitaxel (80mg/m2) on day 1 and 8. After three cycles of chemotherapy, PET-CT showed complete regression of the disease. So the patient underwent total cystourethrectomy, and histological examination showed an almost complete pathological response. External beam radiation therapy was also given to the ileac bone metastasis regions. However, PET-CT taken 17 months after the external beam radiation showed multiple lung metastases. He received GCP chemotherapy again, which resulted in a complete response again after three cycles of chemotherapy. This is the first report on GCP chemotherapy used not only as a salvage chemotherapy but also as a rechallenge regimen for metastatic urachal cancer including a neuroendocrine component. |
| Amo Type | Case Report |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2016-06 |
| 巻 | 70巻 |
| 号 | 3号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 223 |
| 終了ページ | 227 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2016 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 27339213 |
| Web of Science KeyUT | 000379406100011 |
| JaLCDOI | 10.18926/AMO/54414 |
|---|---|
| フルテキストURL | 70_3_159.pdf |
| 著者 | Yoshioka, Takashi| Otsuki, Hideo| Uehara, Shinya| Shimizu, Toshihiro| Murao, Wataru| Fujio, Koji| Fujio, Kei| Wada, Koichiro| Araki, Motoo| Nasu, Yasutomo| |
| 抄録 | Upper urinary tract calculi are common; however, there is no recommended treatment selection for elderly patients. Ureteroscopic holmium laser lithotripsy (URS lithotripsy) is minimally invasive, and it provides a high stone-free rate (SFR) treatment for upper urinary tract calculi. Here, we retrospectively evaluated the surgical outcomes of URS lithotripsy after dividing the 189 cases into 3 groups by patient age: the ʻ＜65 groupʼ (＜65 years old, n＝108), the ʻ65-74 groupʼ (65-74 years old, n＝42), and the ʻ 75 groupʼ ( 75 years old, n＝39). The patientsʼ characteristics, stone status, and perioperative outcomes were assessed. The 65-74 group and the 75 group had a significantly higher prevalence of hypertension compared to the＜65 group. Compared to the＜65 group, the 65-74 group had a significantly higher prevalence of hyperlipidemia, and the 75 group had significantly higher the American Society of Anesthesiologists (ASA) scores. Despite these preoperative risk factors, SFR and postoperative pyelonephritis in the 65-74 group and the 75 group were similar to those of the＜65 group. In conclusion, URS lithotripsy is the preferred treatment for upper urinary tract calculi, even for elderly patients who have multiple preoperative risk factors. |
| キーワード | upper urinary tract calculi ureteroscopy (URS) holmium laser lithotripsy elderly patients stone-free rate (SFR) |
| Amo Type | Original Article |
| 出版物タイトル | Acta Medica Okayama |
| 発行日 | 2016-06 |
| 巻 | 70巻 |
| 号 | 3号 |
| 出版者 | Okayama University Medical School |
| 開始ページ | 159 |
| 終了ページ | 166 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| 資料タイプ | 学術雑誌論文 |
| 言語 | 英語 |
| 著作権者 | CopyrightⒸ 2016 by Okayama University Medical School |
| 論文のバージョン | publisher |
| 査読 | 有り |
| PubMed ID | 27339204 |
| Web of Science KeyUT | 000379406100002 |